✦ LIBER ✦

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study

✍ Scribed by Cengiz Akkaya; Enver Yusuf Sivrioglu; Semra Akgoz; Salih Saygin Eker; Selcuk Kirli

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 106 KB
Volume: 21
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.770

No coin nor oath required. For personal study only.

✦ Synopsis

Objective:

The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (mdd) and mdd with anxiety features to venlafaxine xr.

Method:

Patients with mdd, aging 18 between 65 years, were randomly allocated to two groups receiving either open-label venlafaxine xr capsules (n = 50) or reboxetine tablets (n = 43). subjects were administered hamilton depression rating scale (ham-d) and hamilton anxiety scale (ham-a) at baseline and 2, 4, 7, 10 weeks after the baseline visit.

Results:

Response rates to antidepressant treatment were significantly higher in the venlafaxine xr group at 10th week. when patients having anxious depression were analysed separately; response rate for anxiety of reboxetine group was significantly higher at 7th week only. mean number of side effects were significantly higher in reboxetine group. only one subject in each group was dropped out due to side effect.

Conclusion:

We may suggest that reboxetine is as effective and tolerable as venlafaxine xr in the treatment of mdd and mdd with anxiety features, and it may be considered a treatment option to venlafaxine xr.

📜 SIMILAR VOLUMES

Open trial of nefazodone among Hispanics

Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues

✍ J. Arturo Sánchez-Lacay; Roberto Lewis-Fernández; Deborah Goetz; Carlos Blanco; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

## The efficacy and tolerability of nefazodone in the treatment of major depression among Spanish-monolingual Hispanics was examined and compared to historical controls among English-speaking, predominantly non-Hispanic subjects. Fifty monolingual Hispanic outpatients with major depression and a HAM

Efficacy and tolerability of venlafaxine

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

✍ Per Allard; Lars Gram; Kristina Timdahl; Kirsten Behnke; Martin Hanson; Jesper S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## Background The objectives of the study were to compare efficacy and tolerability of venlafaxine ER 75–150 mg/day with that of citalopram 10–20 mg/day in elderly patients with major depression according to DSM‐IV criteria. ## Methods A randomised, double‐blind, parallel group 6‐mon

Effectiveness and acceptability of sertr

Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison

✍ Prithpal S. Matreja; Dinesh K. Badyal; Prem Khosla; Randhir S. Deswal 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract ## Objective Citalopram and sertraline are widely prescribed selective serotonin reuptake inhibitors (SSRIs). There is no conclusive evidence to show superiority of citalopram or sertraline in terms of efficacy or tolerability. Hence this study was designed to compare short term effica

Effectiveness and tolerability of paroxe

Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea

✍ Chi-Un Pae; Won-Myong Bahk; Duk-In Jon; Sang-Yeol Lee; Bo-Hyun Yoon; Kyung Joon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Abstract ## Objectives This study evaluated the effectiveness and tolerability of paroxetine controlled release (CR) for the treatment of Korean patients with major depressive disorder (MDD) in a naturalistic treatment setting. ## Methods One hundred and ninety patients with MDD were enrolled

The efficacy of reboxetine in the treatm

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study

✍ P. N. Dannon; I. Iancu; L. Grunhaus 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract ## Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibi

Duloxetine and care management treatment

Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study

✍ Jordan F. Karp; Debra K. Weiner; Mary A. Dew; Amy Begley; Mark D. Miller; Charle 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective In older adults, major depressive disorder (MDD) and chronic low back pain (CLBP) are common and mutually exacerbating. We predicted that duloxetine pharmacotherapy and Depression and Pain Care Management (DPCM) would result in (1) significant improvement in MDD and CLBP a